News Releases

BIOMARK Selected to Pitch at 2017 BCTECH Summit

MARCH 16, 2017

Vancouver, British Columbia – (March 16. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is proud to announce that was selected to pitch at #BCTECH Summit, during the Investment Showcase that was scheduled for March 15th 2017 at Vancouver Convention Centre.

President and CEO, Rashid Ahmed says, “BioMark is excited to be amongst the top selected companies to showcase our leading edge cancer diagnostic platform to a dynamic financial investment, government and biotechnology global community”.

About BCTECH Summit

The #BCTECH Summit is the largest technology conference in British Columbia showcasing the province’s vibrant technology industry. From innovations in eHealth data, autonomous vehicles and customer experience, to emerging ideas in cleantech, agritech and aerospace, the two-day event will give you the information and tools you need to move forward in a world where technology is impacting every part of our economy – and our lives.

The #BCTECH Summit brings together tech entrepreneurs, anchor companies, business leaders from traditional industries, investors, government and academia to establish new connections, nurture existing networks, and exchange fresh ideas around innovation driving business growth.

More about the summit is available at http://bctechsummit.ca/

News Release – BIOMARK Selected To Pitch At BCTech Summit 2017 (PDF)

 

———————————————

BIOMARK Invited to Project Pitch Stage For GAPP Application

FEBRUARY 20, 2017

Vancouver, British Columbia – (February 20th. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is proud to announce that it has been successful in the first round of Genome Canada’s Genomic Applications Partnership Program (GAPP) Expression Of Interest submission. BioMark has now been invited to proceed to the Project Pitch Stage that will include a review committee of independent experts.

President and CEO, Rashid Ahmed says, “BioMark is excited to pass through this round of the competition. The estimated project budget is estimated at over $3 million. The funding will be focused on accelerating the commercialization of our metabolomics based diagnostics for lung cancer initially.”

BioMark would like to take this opportunity to thank all the clinical, regulatory and technology advisors and partners for their support during the application process. Information regarding future successful development related to this program will be announced.

About Genome Canada GAPP

The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that have an interest in “pulling” technologies and other results of genomics research from academia to market and application, including industry, government, not-for-profits, and other organizations.

The GAPP aims to:
– Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users – User “pull”;
– Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as well as de-risking and incentivizing follow-on investment from public and private partners;
– Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
– Create and foster a more productive interface between Academia and Users.

Key Parameters of the Program:
Total project size: $300,000 to $6 million. The structure of the funding plan is as follows: 1/3 investment from Genome Canada, 1/3 provided by the User partner (cash or in-kind) and 1/3 of other co-funding.

Project term: 1-3 years. A shorter or longer term will be considered, but only if a strong rationale is provided.

Project stage: small-scale proof-of-concept or pilot projects through to large-scale projects. Projects should not be in the discovery phase.

To be eligible for the GAPP, a project must:
– respond to the objectives of the GAPP
– represent an active partnership between Academic(s) and User(s)
– propose to develop, enhance or validate a genomics-derived solution (i.e., a product, tool or process whose origin is based in genomics or related disciplines such as bioinformatics, epigenomics, metabolomics, metagenomics, nutrigenomics, pharmacogenomics, proteomics and transcriptomics);
– address key challenges or opportunities defined by the User that require a partnership with Academia (i.e., User “pull”); and
– focus on downstream R&D activities.

Application Process
There is a three-stage gated application process for this program:

1. Expression of Interest (EOI)
2. Project Pitch
3. Supplementary Proposal

News Release – BIOMARK’s GAPP Success (PDF)

 

———————————————

BioMark Completes Data Collection And Submits Data for Analysis prior to Health Canada Submission

JULY 5, 2016

Vancouver, British Columbia – (July 5, 2016) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, OTCQB:BMKDF; FSE: 20B), a leader in next-generation cancer diagnostics using metabolites, is pleased to announce that its designated analytical service provider Biopharmaceutical Research Inc (BRI) has completed the raw data collection for the 200 patient trial using an internal standard developed for BioMark that meets Health Canada and US FDA standards.

A data transfer specification agreement has been signed with BRI for the raw data to be sent to a biostatistician and the regulatory group in Manitoba for further analysis and review prior to formulating a comprehensive report for Health Canada.

The internal standard for the assay analysis was established by Biopharmaceutical Research Inc. (BRI), and meets U.S. Food and Drug Administration (FDA) and Health Canada requirements. The trials were conducted in Canada and Bangladesh and focused on lung, breast and GI cancers. Assay validation methods are completed to ensure that an analytical methodology is accurate, specific and reproducible over the specified range that a target will be analyzed. Assay validation provides an assurance of reliability during normal use.

“BioMark anticipates to prepare and submit a detailed report to Health Canada by end of this summer 2016. This will be a pivotal event for the company,” said BioMark President and CEO Rashid Ahmed.

About Biopharmaceutical Research Inc. (BRI)

Biopharmaceutical Research Inc. is a specialized analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and NDA-enabling studies.

The bioanalytical LC/MS/MS group was founded by Dr. David Kwok and has been operating since 1999. Over the years BRI has performed hundreds of quantitative assays on small molecule drugs, metabolites and chemical biomarkers supporting Phase I to IV clinical PK samples and DM/PK preclinical samples. Bioanalytical assay experience includes immunochemical ELISA and cell-based assays of small molecule chemical biomarkers and large molecules.

BRI meets the following Good Laboratory Practice Regulations/ Standards/ Guidelines:

  • U.S. Food and Drug Administration, Title 21 Code of Federal Regulations Part 58, Current
  • Organization for Economic Cooperation and Development
  • The OECD Principles of Good Laboratory Practice, Series on Principles of Good Laboratory Practice and Compliance Monitoring, Monograph No.1 to 14, current
  • Japanese Ministry of Health and Welfare, Ordinance No. 21, April 1, 1997

 

BioMark Announce Progress Towards Data Analysis  (PDF)

 

———————————————

BioMark Closes Second Tranche of Private Placement Offering

JUNE 24, 2016

Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce that further to its press release dated June 20, 2016, it has closed the second tranche of a non-brokered private placement for gross proceeds of $163,615 wherein BioMark issued 1,090,767 units at a price of $0.15 per unit.

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.30 per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finder’s fees are payable on the private placement.

BioMark closed the first tranche of the private placement on March 15, 2016 for proceeds of $408,954. The aggregate proceeds from the offering to date are $572,569.

The proceeds of the private placement will be used for the continuation of the company’s phase 3 clinical trials, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months and one day from the closing date of the private placement. Certain Insiders, Directors and Officers may subscribe for a portion of this placement.

 

F-Press_Release_-_Second_Tranche_Private_Placement_-_$0_15_units_-_June_2016 (PDF)

 

———————————————

BioMark Engages Stockhouse.com Deal Room with Private Placement

JUNE 20, 2016

Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce it has engaged Stockhouse Deal Room in connection with closing the second tranche of its current private placement.

Private Placement

The private placement was recently increased from 4,000,000 to 6,500,000 units at a price of $0.15 per unit for maximum total proceeds of $975,000. Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.30 per share for a period of one year from the grant date. BioMark closed the first tranche of the private placement on March 15, 2016 for proceeds of $408,954.

The private placement offering will be conducted in the provinces of British Columbia, Alberta, and Quebec to qualified investors under National Instrument 45-106 Prospectus Exemptions.

Stockhouse Deal Room

The Stockhouse Private Deal Room is a portal for qualified investors to view and participate in private placement financings of public companies. Interested investors are invited to view further details of our current private placement at stockhouse.com c.bux.

President and CEO of BioMark Rashid Ahmed, stated the following regarding Stockhouse Deal Room: “We’re utilizing the Stockhouse Deal Room (http://www.stockhouse.com/dealroom) in order to offer faster and more economical private placement medium for investors to participate.”

 

F1-Press_Release_-_Engage_Stock_House_Deal_Room_-_June_2016 (PDF)

 

———————————————

Biomark Receives Approval For Its Lung Cancer Treatment Protocol

MARCH 29, 2016

Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce that it has now completed its response to lung cancer treatment protocol and has successfully been granted approval by both Health Canada and the Ethics Review Board. Having received both approvals for this protocol, the Company can now commence its preliminary pilot study at CancerCare Manitoba, expected to commence late April 2016.

President and CEO of BioMark Rashid Ahmed states: “Health Canada approval for our lung cancer treatment protocol is an important achievement for BioMark. Our technology offers real clinical value and offers physicians a cheaper and faster prognosis biomarker for prediction of chemotherapy response as well as a positive/negative indicator of the prognosis for patients with a lung cancer diagnosis. This is a large and underserved market that BioMark intends to additionally capture. We anticipate 2016 to be a milestone year for the Company with the completion of the 200 patient clinical trial and the commercialization of its early detection red alert technology.”

BioMark’s technology platform is robust and can be used as a Cancer Management System with application in early detection, measuring response to both drug and surgical treatment and potentially for serial cancer monitoring. BioMark is investigating and continually developing multiple clinical applications of its platform metabolomics based technology. The Company has recently closed the first tranche of private placement of over $400,000 CAD to be used for the continuation of the company’s clinical trials, marketing initiatives and general working capital.

 

Background

Current projections predict a substantial increase in cancer rates in the general population. Currently 1 in 4 deaths in the United States is due to cancer, making it the second leading cause of death, behind cardiac disease. Within 10 to 15 years cancer will overtake cardiovascular disease as the leading cause of death. Although the American Cancer Society recommends that those over 40 years of age undergo yearly cancer check-ups, this recommendation is usually not followed. When patients present to their physicians with symptoms of cancer at a later stage of development, survival tends to be poorer.

For advanced-stage malignant disease, systemic chemotherapy is one of the main choices for therapy. The objectives are usually palliative in intent: i.e., to maintain or improve symptoms and quality of life, with the additional benefit of improving the survival duration – though falling short of cure in most cases. Evaluation of response is often challenging as it may require several months to assess regression using conventional techniques of physical examination, radiographic studies and/or conventional laboratory biochemistry studies. Serum tumour markers provide early indications but are not available for many common types of cancer such as lung cancer. Therefore, many patients may endure side-effects of therapy for several months before clinicians are able to determine if therapy will be effective in achieving the intended therapeutic outcomes.

 

Press Release – BUX – Expansion of Cancer Platform (PDF)

 

———————————————

BioMark Announces Private Placement Offering

MARCH 9, 2016

Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce a non-brokered Private Placement for up to 4,000,000 Units at a price of $0.15 per Unit to raise gross proceeds of up to $600,000. Each Unit will consist of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.30 per share for a period of one year from the closing date of the private placement.

President and CEO of BioMark Rashid Ahmed states: “This is an exciting time for BioMark as we work towards completing our formative phase 3 clinical trial utilizing our unique, non-invasive early cancer detection technology. We anticipate 2016 to be a milestone year for the Company with the completion of clinical trial and the commercialization of our early detection platform.”

The proceeds of the private placement will be used for the continuation of the company’s phase 3 clinical trials, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months and one day from the closing date of the private placement. Certain Insiders, Directors and Officers may subscribe for a portion of this placement. Finder’s fees may be payable.

The warrants are subject to an accelerated expiry provision where, if at any time after the closing date of the offering of the units, the closing price of the common share is $0.50 or higher for a period of 10 consecutive trading days, the company may provide notice by way of press release to the holder of the warrants of the early expiry of the warrants. Thereafter the warrants shall expire on that date that is 30 days from the date that notice is given.

 

Press Release – Biomark Announces Private Placement-March 9 2016 (PDF)

 

———————————————

BioMark Closes First Tranche Of Private Placement Offering

MARCH 15, 2016

Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce that further to its press release of March 9, 2016, it has closed the first tranche of a non-brokered private placement for gross proceeds of $408,954 wherein BioMark issued 2,726,360 units at a price of $0.15 per unit.

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.30 per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finder’s fees are payable on the private placement.

The proceeds of the private placement will be used for the continuation of the company’s phase 3 clinical trials, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months and one day from the closing date of the private placement. Certain Insiders, Directors and Officers may subscribe for a portion of this placement.

President and CEO of BioMark, Rashid Ahmed, states: “This is an exciting time for BioMark as we work towards completing our formative phase 3 clinical trial utilizing our unique, non-invasive early cancer detection technology. We anticipate 2016 to be a milestone year for the Company with the completion of clinical trial and the commercialization of our early detection platform.”

 

Press Release – Biomark Closes Partial Private Placement-March 15th 2016 (PDF)

 

———————————————

BioMark Announces Progress Towards Data Analysis

FEBRUARY 16, 2016

VANCOUVER, British Columbia (February 16, 2016) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces that BioMark has completed the internal standards for its assay to meet both Health Canada and FDA requirements for the 200 patient trial completed in Fall of 2015.

 

Rashid Ahmed, CEO and President of BioMark states that “data transfer agreement form from BRI, regarding the data from the urinary analysis of N-Acetylamantadine of the study samples is expected to be signed between Saint Boniface Research Centre (SBRC) by middle of February 2016. Saint Boniface’s unit statistician will perform appropriate statistical analyses and will generate a report for BioMark’s scientific and regulatory team to review. It is expected to take approximately 10 weeks to complete the analysis and to generate a report. Submission to Health Canada will follow pending the robustness of the data. All the submission work will be led by SBRC team based in Manitoba”.

 

Standards

The internal standard for the assay analysis was established by Biopharmaceutical Research Inc. (BRI), and meets U.S. Food and Drug Administration (FDA) and Health Canada requirements. The trials were conducted in Canada and Bangladesh and focused on lung, breast and GI cancers. Assay validation methods are completed to ensure that an analytical methodology is accurate, specific and reproducible over the specified range that a target will be analyzed. Assay validation provides an assurance of reliability during normal use.

 

About BRI

Biopharmaceutical Research Inc. is a specialized analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and NDAenabling studies. The bioanalytical LC/MS/MS group was founded by Dr. David Kwok and has been operating since 1999. Over the years BRI has performed hundreds of quantitative assays on small molecule drugs, metabolites and chemical biomarkers supporting Phase I to IV clinical PK samples and DM/PK preclinical samples.

Bioanalytical assay experience includes immunochemical ELISA and cell-based assays of small molecule chemical biomarkers and large molecules. BRI meets the following Good Laboratory Practice Regulations/ Standards/ Guidelines:

  • U.S. Food and Drug Administration, Title 21 Code of Federal Regulations Part 58, Current
  • Organization for Economic Cooperation and Development
  • The OECD Principles of Good Laboratory Practice, Series on Principles of Good Laboratory Practice and   Compliance Monitoring, Monograph No.1 to 14, current
  • Japanese Ministry of Health and Welfare, Ordinance No. 21, April 1, 1997

 

BioMark Announce Progress Towards Data Analysis (PDF)

 

———————————————

BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer

Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator

SEPTEMBER 10, 2015

VANCOUVER, British Columbia (September 10, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces that it expects to begin conducting studies in the fourth quarter of 2015 to validate the use of its patented assays to determine response to surgical intervention for patients with lung cancer, and to further offer a personalized and reliable indicator to monitor persistence, recurrence, or state of a tumour. Dr. James Bond, Chief of Surrey Memorial Hospital Thoracic Surgery Team, along with the entire thoracic surgical division of Fraser Health Authority that includes Drs. Ahmad Ashrafi, Sharon Ong, and Kyle Grant, will serve as principal investigator for this formative clinical validation study entitled “The use of BioMark’s Acetyl Amantadine patented technology to assess surgical intervention for lung cancer.” Fraser Health Authority is one of the largest, fastest growing health care authorities in Canada serving a population of 1.8 million encompassing 12 regional hospitals. It has the largest and busiest thoracic surgery program in British Columbia. In addition, Dr. Daniel Sitar of CancerCare Manitoba will also act as co-principal investigator.

President and CEO of BioMark Rashid Ahmed stated, “Lung cancer is the most devastating cancer with very low five-year survival rates. Having access to an effective, non-invasive means of assessing and monitoring this cancer would be highly beneficial for this group of patients. We believe that our assay could offer a valuable diagnostic tool for surgical oncologists to assess the clinical success and potential recurrence of cancer. We are honored to have Dr. Bond and the distinguished team at Surrey Memorial Hospital working with us. We expect to begin this trial in the fourth quarter of 2015, subject to ethics approval from Fraser Health Authority.”

Dr. Bond says, “At present, we have numerous diagnostic modalities to facilitate the diagnosis and staging of lung cancer. Each of these current modalities is expensive, at risk of false negative results (that is, will miss a cancer diagnosis), has long waitlists to gain access to these tests and, in the end, requires a specialist (thoracic surgeon) to put all the details together to then plan for treatment. Surgery is still the most important part of cancer cure therapies. Under our current paradigm of care, an interventional procedure is most often used to acquire tissue to confirm a diagnosis. This might mean a bronchoscopy or a lung biopsy performed in the radiology department. As lung biopsies are frequently non-diagnostic, as are bronchoscopies, many of these tests serve to delay definitive treatment while also costing the health care system an immense amount of money for results that are not helpful.

“A urine or blood test used to diagnose lung cancer, and then used again to monitor for recurrence after treatment, has the potential to radically change how we diagnose, and then treat, lung cancer. A urine or blood test will be substantially faster, saving weeks or even months searching for a diagnosis. It will expedite referral to a surgeon or other specialists directly from the general practitioner after a positive blood test. This will result in faster access to curative treatments. As a urine or blood test will have significantly lower costs and without the risk of complications of other tests such as bronchoscopies and lung biopsies, the health care system can redirect those savings where they might be more needed.

“Simply put, a urine or blood test for lung cancer will save lives, will save time, and will save health care dollars. The need for such technologies cannot be overstated. This is an important study with far-reaching implications for lung cancer and other cancers as well,” added Dr. Bond.

 

About Dr. James Bond

Dr. Bond is a healthcare innovator with a track record of overcoming inertia and streamlining processes. At Surrey Memorial Hospital, he has led a Rapid Autopilot Program (RAP) to speed up lung cancer wait times from an average of 190 days to 45 days. When a patient receives abnormal lung imaging, he/she is immediately appointed a nurse navigator, who is responsible for planning his/her care and sending imaging to the surgeon for his insight. Dr. Bond is an innovative thoracic surgeon, who has led the adoption of the MATRIX thoracic surgical procedure and created a comprehensive program of care at Surrey Memorial Hospital that is the only one of its kind in Canada. The innovative surgery improves survival rates, reduces lengthy hospital stays and improves long-term outcomes by mitigating chronic pain and breathlessness. Dr. Bond currently trains other doctors in North America on the procedure.

BioMark Diagnostics to Conduct Validation Studies (PDF)

 

———————————————

BioMark Diagnostics Receives Clearance from Health Canada to Commence Clinical Trial with Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer

SEPTEMBER 9, 2015

Vancouver, British Columbia (September 9, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces receipt of a No Objection Letter from Health Canada, clearing the way for a clinical trial with the company’s metabolite-based assay using a urine sample to measure response to treatment for lung cancer.

The trial will specifically look at lung cancer and response to treatment while the company continues it’s ongoing Phase III trial for BioMark’s early stage, low cost general screening test which currently has 200 samples preparing to be analyzed.

The trial will recruit patients with lung cancer who are being treated with chemotherapeutics with enrollment expected to begin during the fourth quarter of 2015. Dr. Andrew Maksymiuk, Medical Oncologist at CancerCare Manitoba and Professor in the Faculty of Medicine at the University of Manitoba, will be the principal investigator. In 2014, Dr Maksymiuk was awarded the Joan K. Mauer Memorial Quality Assurance Award by the Cancer Therapy Evaluation Program of the U.S. National Cancer Institute. Dr. Daniel Sitar, Professor Emeritus in the Faculty of Medicine at the University of Manitoba, will serve as co-principal investigator. The trial will be conducted at CancerCare Manitoba along with the clinical support from the staff at Saint Boniface Research Centre located in Winnipeg, Manitoba.

“Lung cancer is North America’s most deadly cancer, and the ability to use clinical biomarkers to assess a patient’s response to chemotherapeutics can be highly effective for quickly developing and managing a time-sensitive, personalized treatment regime,” said BioMark’s President and CEO Rashid Ahmed. “A faster treatment prognosis allows a doctor to course correct or guide a treatment plan when time is of the essence. The result would be very beneficial to a patient, medical community and the paying institutions.”

“Our patented assay, which uses a urine sample, can be easily adopted into routine clinical practice,” added Mr. Ahmed. “This clinical trial is one of several steps we are taking to bring this technology to physicians and their patients, and to reinforce BioMark as a life-saving brand. We are honored to have Drs. Maksymiuk and Sitar leading this clinical trial.”

 

About BioMark’s Non-Invasive, Urine-Based Assay

BioMark’s assay consists of screening for the acetylated form of the drug Amantadine given to patients prior to measurement via LC MS in body fluids. This acetylation is performed by the enzyme Spermine/Spermidine N-Acetyl Transferase (SSAT). It has been documented that elevated levels of SSAT are observed in many cancers including lung, breast, prostate, melanoma and gastric cancers. Clinical trials conducted with both cancer and healthy subjects have provided proof of principle. In addition, analysis of SSAT mRNA levels in tissue samples allows determination of cancer type.

Sept 9thBioMark Diagnostics Receives Clearance from Health Canada (PDF)

 

———————————————

BioMark Diagnostics to Present at Rodman & Renshaw Global Investment Conference

SEPTEMBER 3, 2015

VANCOUVER, British Columbia (September 3, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces that President and CEO Rashid Ahmed will present a company overview at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015, at 10:50 a.m. Eastern time (7:50 a.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.

“We are excited about the opportunity to increase visibility for our ultra-early oncology diagnostic technology with leading U.S. institutional investors attending this premier biotechnology conference,” said Mr. Ahmed. “We understand the importance of having a strong operating presence in the U.S. and we are committing resources to successfully execute on the U.S. strategy we recently unveiled.”

A webcast of the presentation will be available at www.biomarkdiagnostics.com/investor-relations/corporate-presentations-and-updates/. A replay of the webcast will be available following the presentation.

BioMark Diagnostics to Present at Rodman & Renshaw Global Investment Conference (PDF)

 

———————————————

BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis

AUGUST 19, 2015

Vancouver, British Columbia – (August 19, 2015) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF), a leader in next-generation diagnostics using metabolites, is pleased to announce that the assay validation to analyze the clinical samples from the Company’s first 200-patient trial is anticipated to be completed within four weeks.

The internal standard for the assay analysis was established by Biopharmaceutical Research Inc. (BRI), and meets U.S. Food and Drug Administration (FDA) and Health Canada requirements. The trials were conducted in Canada and Bangladesh and focused on lung, breast and GI cancers. Assay validation methods are completed to ensure that an analytical methodology is accurate, specific and reproducible over the specified range that a target will be analyzed. Assay validation provides an assurance of reliability during normal use.

“We conducted this trial to build on our proven ability and clinical success in using a simple urine sample to accurately diagnosis cancer in its very early stages,” said BioMark President and CEO Rashid Ahmed. “Trial samples will be analyzed and data generated after the assay validation is completed. It is vitally important to have a rigorous standard established that meets and exceed regulatory requirements. BRI offers third-party validation services under a GLP/GMP environment and the results can be reliably presented for regulatory applications in the U.S. and Canada. Completion of this phase is critical in generating data that can be submitted to Health Canada and later to FDA for final approval.”

 

About Biopharmaceutical Research Inc. (BRI)

BRI Biopharmaceutical Research Inc. is a specialized analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and NDA-enabling studies.

The bioanalytical LC/MS/MS group was founded by Dr. David Kwok and has been operating since 1999. Over the years BRI has performed hundreds of quantitative assays on small molecule drugs, metabolites and chemical biomarkers supporting Phase I to IV clinical PK samples and DM/PK preclinical samples. Bioanalytical assay experience includes immunochemical ELISA and cell-based assays of small molecule chemical biomarkers and large molecules.

BRI meets the following Good Laboratory Practice Regulations/ Standards/ Guidelines:

  • U.S. Food and Drug Administration, Title 21 Code of Federal Regulations Part 58, Current
  • Organization for Economic Cooperation and Development
  • The OECD Principles of Good Laboratory Practice, Series on Principles of Good Laboratory Practice and Compliance Monitoring, Monograph No.1 to 14, current
  • Japanese Ministry of Health and Welfare, Ordinance No. 21, April 1, 1997

BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis_1 (PDF)

 

———————————————

BioMark Diagnostics Unveils U.S. Strategy

AUGUST 13, 2015

Vancouver, British Columbia – (August 13, 2015) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE: 20B), a leader in next-generation diagnostics using metabolites, announces its strategy to expand operations into the U.S. with headquarters in Maryland’s world-class biotechnology center.

“Expansion of operations into the U.S. market is a critical step in our growth plan,” said Rashid Ahmed, BioMark’s President and CEO. “This move will support our ability to build upon our leadership position in developing highly sensitive diagnostics that can detect cancer at its very early stages using our proprietary metabolite approach. We are making significant progress in strengthening the clinical validation for our metabolite approach and we are looking to build on the BioMark brand in the U.S. market.”

Key aspects of the BioMark U.S. strategy include:

  • Expanding BioMark operations into the U.S. by establishing U.S. headquarters in the Maryland biotechnology center.
  • Appointing Dr. Thomas Malcolm as Chief Scientific Officer and Head of U.S. Operations, to lead its U.S. operations, as previously announced.
  • Submitting our SSAT-1 Acetyl Amantadine assay for regulatory approval to first Health Canada in the first half of 2016 and later to U.S. Food and Drug Administration (FDA). BioMark is currently in the process of collecting and validating additional data points in preparation for these submissions.

“We are basing our decision to expand operations to Maryland on the strength and reputation of its biotech ecosystem, as well as an invitation from Maryland’s Department of Business and Economic Development’s BioMaryland Center,” added Mr. Ahmed. “We believe that locating our U.S. operations in Maryland will support our efforts to collaborate with leading academic and clinical institutions, which is a vital part of our growth strategy. We already have key ties with critical suppliers and luminary research engineers in Maryland and adjacent states, including Diagnostic anSERS Inc., a producer of affordable ink-jet printed surface enhanced raman spectroscopy (SERS) substrates. This is an important part of our future development plans.”

The state of Maryland has been recognized for its premier center for biotechnology innovation and supportive infrastructure, and is strategically located in close proximity to the FDA and the National Cancer Institute.

Biomark US Strategy (PDF)

 

———————————————

BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations

AUGUST 11, 2015

Vancouver, British Columbia – (August 11, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce the appointment of Thomas Malcolm, Ph.D., as Chief Scientific Officer and Head of U.S. Operations. Dr. Malcolm will be responsible for establishing and developing BioMark’s operations in the U.S.

“Tom is an excellent addition to our core management team, bringing us solid scientific expertise and an in-depth understanding of next-generation diagnostics powered by metabolomics,” said Rashid Ahmed, BioMark President and CEO. “A key aspect in our strategy is to expand into the U.S. market and Tom’s experience will be invaluable in this transformation. I welcome Tom to our team and we look forward to adding more critical members to our U.S. team under his leadership.”

“This is a great opportunity for me to be part of the new wave of diagnostic technologies utilizing metabolomics-based assays,” said Dr. Malcolm. “I believe that BioMark’s unique approach and technology platform will play an instrumental role in offering the medical community better and more economical tools to manage and treat cancers. BioMark’s team and scientific collaborators all bring immense global expertise and depth. It will be my privilege to join the team.”

Dr. Malcolm is founder and CEO of Criterion BioScience Capital Group, a growing New York-based pharmaceutical research company that provides scientific and business analysis to hedge funds and private investors. He previously was a senior biochemist at Siemens Healthcare Diagnostics, where he directed a team of research scientists for the development of ELISA-based diagnostic assays and was responsible for assay development, design and validation.   Dr. Malcolm worked as a Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center and Mount Sinai School of Medicine, with a focus on the regulation of genes relating to various cancers. He graduated from the University of British Columbia with Ph.D. in Biochemistry and Molecular Biology, with a focus on gene regulation in viral models.

BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations (PDF)

 

———————————————

BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant

JULY 29, 2015

Vancouver, British Columbia – (July 29, 2015)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with David Chen, Ph.D., Professor, Department of Chemistry at the University of British Columbia, to develop a novel sample enrichment method for surface-enhanced Raman spectrometry (SERS) detection.

“We are developing metabolomics-based diagnostic assays for the ultra-early, non-invasive detection of cancer before tumors become metastatic and symptomatic,” said BioMark President and CEO Rashid Ahmed. “Our approach detects enzymes that are over expressed in cancer cells through a urine sample. The future of our technology includes a novel application of SERS that could allow for its use via hand-held equipment. Incorporating important clinical and technical features into our SERS system will enhance its clinical utility by increasing its sample handling capability and improving its sensitivity and signal specificity.

“We are delighted to be working with Dr. Chen and his team at the University of British Columbia to help BioMark advance this critical project. Dr. Chen has significant expertise in chemical separation, ultra-trace detection and clinical diagnostics. He will direct the project and supervise the design of a novel analytical system that can provide greater separation power in detection of metabolites of interest,” Ahmed explained. “We are grateful to the Canadian government for awarding BioMark yet another grant that supports our work to advance this important technology toward commercialization.”

About National Sciences and Engineering Research Council of Canada (NSERC) Engage Grants

Engage Grants are intended to foster the development of new research partnerships between academic researchers and companies, and supports research and development projects aimed at addressing a company-specific problem. This $25,000 grant extends over a six month period.

 

BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant (PDF)

 

———————————————

BioMark Diagnostics Engages LHA for Investors Relations

JUNE 29, 2015

Vancouver, British Columbia – (June 29, 2015) – BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces that it has engaged LHA to support its investor relations program in the U.S. market.

“We recognize the importance of expanding our investor relations outreach,” said BioMark President and CEO Rashid Ahmed. “In recent years, the U.S. investment community has shown significant interest in the biotechnology sector and we are excited to introduce BioMark and our novel, disruptive technology to this receptive market. Given their understanding of the opportunity, and proven track record for establishing messaging that resonates with investors and increasing Street awareness for companies like BioMark, we view LHA as an ideal choice. LHA is the right partner for BioMark at the right time.”

 

About LHA

Founded in 1984, LHA (formerly Lippert Heilshorn & Associates) is a leading provider of investor relations services. Staffed by a team of professionals with deep experience across multiple industry sectors, LHA partners with public and private companies to define objectives, set strategy and implement custom-designed programming utilizing industry best practices. By creating client identity and communicating strategic vision, LHA builds awareness, enthusiasm and sponsorship among target audiences to maximize shareholder value.

 

BioMark Engages LHA (PDF)

 

———————————————

Biomark Secures DTC Eligibility

MAY 28, 2015

Vancouver, British Columbia – (May 28, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF) is pleased to announce that it has secured The Depository Trust Company (DTC) eligibility for its shares traded in the United States under the symbol BMKDF.

“DTC eligibility allows BioMark to significantly expand its U.S. and international shareholder base, increases the efficiency, and lowers the cost associated of trading BioMark stock in the US,” said Rashid Ahmed, President and CEO of BioMark Diagnostics Inc.. “Securing DTC eligibility reflects our ongoing efforts to support our growing investor base in the U.S. who can now purchase and trade the securities more efficiently through their brokers.”

BioMark will continue to trade on the Canadian Stock Exchange under its existing symbol BUX.

 

About DTC

The DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers. Securities that are not DTC-eligible are often not accepted for trading at many brokerages due to the amount of paperwork and manpower required to execute and settle trades, thus making it more difficult for a significant percentage of investors to access the shares. Additionally companies that are approved for DTC electronic transfers often experience higher trading volumes in their stock given the additional accessibility and availability of shares for trading.

 

Press Release – BIOMARK SECURES DTC ELIGIBILITY (PDF)

 

———————————————

BioMark Receives No Objection Letter From Health Canada

MAY 26, 2015

Vancouver, British Columbia – (May 26, 2015) – BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has received a no objection letter (“NOL”) to extend its trials in both Canada and Bangladesh from Health Canada’s Office of Clinical Trials.

Rashid Ahmed, President and CEO, comments: “This marks another milestone for BioMark and allows the company to gather more representative data for analytical purposes especially for the types of cancers that BioMark is currently building its diagnostics and screening applications and platform for. Following Health Canada clearance, the extended trials will allow BioMark to gather more data, which can potentially allow BioMark to demonstrate the efficacy of its cancer diagnostic tests that we believe has significant medical, patient and commercial opportunity”.

 

BioMark Receives No Objection Letter From Health Canada (PDF)

 

———————————————

BIOMARK’s Clinical Technology Center at Innovation Boulevard in Surrey BC

APRIL 27, 2015

Vancouver, British Columbia – (April 27, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that it will be setting up an office at the “Health Technology Innovation Hub” located at 13737 96th Avenue, Surrey, BC starting May 1st 2015.

President and CEO of BioMark, Rashid Ahmed says: “This new office will be the Canadian clinical technology gateway center for BioMark as we develop and prime technologies for commercialization. The facilities, environment and location are an ideal convergence for technology development and testing. Accesses to physicians, researchers, instruments and active support from the Health Tech Innovation Foundation allow BioMark to practically accelerate our test, design and introduce medical technologies and solutions in an ideal setting. The facilities and site provides BioMark the perfect ecosystem to accelerate our technology development at point of care while leveraging the excellent resources available within this dynamic “hub”.”

 

About Innovation Boulevard

Innovation Boulevard is an area consisting of 1 square mile in Surrey City Centre encompassing Surrey Memorial Hospital – Simon Fraser University – 3 other Academic institutions – 9 Technology Test beds and over 188 medical related businesses. Innovation Boulevard is an agile partnership of health, business, higher education and government creating new health technologies to improve peoples’ lives. Its focus is on 3 technology areas: medical devices, independent living and digital health. Innovation Boulevard’s shared vision is to achieve remarkable results in 4 areas:

  1. Improve health outcomes.
  2. Implement intelligent solutions for the health care system.
  3. Attract talented clinicians and researchers.
  4. Grow companies in health care technology and services sectors.

 

Press Release – BIOMARK’s New Office Site at Innovation Boulevard (PDF)

 

———————————————

BioMark Presents At 11th Annual Conference of the Metabolomics Society

APRIL 14, 2015

Vancouver, British Columbia – (April 14, 2015)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that BioMark has been selected to present at 11th Annual Conference of the Metabolomics Society.

“BioMark has been accepted to be a presenter at the 11th annual conference of the Metabolomics Society, to be held in San Francisco/Burlingame between June 29 and July 02, 2015. Over 700 abstract submissions have been received. All abstracts were scored by the International Organizing Committee by around six reviewers per abstract to yield a fair score. BioMark has been selected to present a 90 minute long poster presentation in the session provisionally titled “poster session 1-3”. We very much look forward to an exciting meeting,” says Oliver Fiehn, PhD Chairman For Organizing Committee, Metabolomics Society.

President and CEO, Rashid Ahmed is delighted to have this opportunity to present BioMark’s technology in the rapidly expanding field of metabolomics with partners from TMIC, a Genome Canada-funded Science and Technology Innovation Centre located at the University of Alberta and University of Victoria.

President and CEO of BioMark, Rashid Ahmed says: “Metabolomics for diagnostic application is a crucial component of BioMark’s cancer detection and monitoring platform.”

BioMark Presents At 11th Annual Conference of the Metabolomics Society (PDF)

 

———————————————

BioMark Receives NSERC Engage Grant for Raman Enhancement with Dr. SAFIEDDIN SAFAVI-NAEINI

APRIL 7, 2015

Vancouver, British Columbia – (April 7, 2015)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has received a grant from NSERC to partner with Dr. Safieddin Safavi-Naeini for further enhancement of its Raman Spectroscopy system.

Rashid Ahmed, President and CEO, comments: “Our goal is to expand the global utility of BioMark’s surface enhanced Raman system by incorporating important technical features that could increase our capability to help transfer data from our worldwide studies. Dr Safavi-Naeini’s team at the University of Waterloo is a perfect group to help BioMark in this critical project.”

Dr. Safieddin Safavi-Naeini, Ph.D. is Professor in the Electrical and Computer Engineering Department and holds NSERC/Blackberry Industrial Research Chair in Intelligent Integrated Radio and Photonics at the University of Waterloo. Dr. Safavi-Naeimi is a leading hardware expert.

BioMark is very thankful for the continued support from the Canadian government.

 

About National Sciences and Engineering Research Council of Canada (NSERC) Engage Grants

NSERC Engage Grants are intended to foster the development of new research partnerships between academic researchers and companies and supports research and development projects aimed at addressing a company-specific problem.

 

BioMark Receives NSERC Engage Grant (PDF)

 

———————————————

BioMark Receives BIAP funding from NRC-IRAP

MARCH 31, 2015

Vancouver, British Columbia – (March 31, 2015)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has been awarded by NRC – IRAP the Business Innovation Access Program (BIAP) funding for development and optimization of its novel recombinant antibodies.

Rashid Ahmed, President and CEO, comments “This project will help optimize the potential production recombinant antibodies with work to be conducted by Dr. Bach at UBC. These antibodies will be critical in the commercial development of our cancer diagnostic kits. We are excited to be able to develop the antibodies with rich features that can help secure source and quality necessary for medical application kit development”.

BioMark would like to thank both NRC and UBC for their help in this endeavor that can yield both medical and economic benefit to Canada at large.

 

BioMark Receives BIAP funding from NRC-IRAP (PDF)

 

———————————————

BioMark Announces Partnership With The Metabolomics Innovation Centre

MARCH 27, 2015

Vancouver, British Columbia – (March 27, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has partnered with The Metabolomics Innovation Centre (“TMIC”), a Genome Canada-funded Science and Technology Innovation Centre located at the University of Alberta and University of Victoria. TMIC provides scientific expertise, analytical services, bioinformatics tools, and customized technology development which complements BioMark’s future research directions in lung, prostate, breast and colon cancer. This relationship will strengthen BioMark’s capabilities and resources in the discovery, validation and translation of future metabolomic-based diagnostic tests for early cancer detection. In collaboration with TMIC, BioMark plans to develop additional novel tests for point-of-care testing. Dr. David Wishart, Professor at the University of Alberta and Director of TMIC states: “TMIC is very excited about collaborating with BioMark to develop and identify new metabolite biomarkers in early lung cancer detection and potentially for assessing response to treatment. TMIC looks forward to a very productive collaboration with BioMark. “

Both TMIC and BioMark will be presenting an abstract at the 11th International Conference of The Metabolomics Society to be held between June 29th to July 2nd at the University of California, Davis USA.

President and CEO of BioMark, Rashid Ahmed says: “We are delighted to be collaborating with TMIC which is Canada’s leading centre for advancement in metabolomics. This is a strategic partnership for BioMark since our technology is metabolomics based.”

About TMIC:

The Metabolomics Innovation Centre (TMIC) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes $20 million in state-of-the-art metabolomics equipment and ongoing investment for “omics” research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMIC’s technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications such as human health and disease, petroleum research, forensics, food and nutrition, anti-doping, and textile sciences. TMIC provides access to cutting-edge metabolomic and bioinformatics technologies for Genome Canada-funded projects and the broader research community including government, academia and industry. For more information, visit www.metabolomicscentre.ca.

 

BIOMARK_ANNOUNCES_PARTNERSHIP_WITH_THE_METABOLOMICS_INNOVATION_CENTRE (PDF)

 

———————————————

BioMark Added To Cse Composite Index

MARCH 25, 2015

Vancouver, British Columbia – (March 25, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF) is pleased to announce that BioMark has been added to the CSE Composite Index (“ Index”), effective after the close of trading on Friday, March 20, 2015, as a result of CSE’s quarterly rebalancing of the Index.

Rashid Ahmed, President and CEO of BioMark Diagnostics Inc. states “we are very pleased to have been selected for inclusion in the CSE Composite Index, a primary indicator of market activity for Canadian capital markets. This demonstrates our ongoing dedication to achieve progress for our shareholders. This inclusion also provides our exposure to a broader range of potential investors and improves liquidity for our securities”.

 

BIOMARK_ADDED_TO_CSE_COMPOSITE_INDEX_ (PDF)

 

———————————————

Biomark Announces Grant Funded Partnership With TMIC

MARCH 2, 2015

Vancouver, British Columbia – (March 2, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB : BMKDF)

BioMark Diagnostics Inc. is proud to announce that it has obtained NSERC Engage Grant partnership funding in collaboration with Dr. David Wishart, Director of The Metabolomics Innovation Centre (TMIC) at the University of Alberta.

President and CEO Rashid Ahmed says, “We are delighted to enhance our collaboration with Dr. Wishart and TMIC at the University of Alberta. The collaboration to research, validate and establish additional biomarkers with a premier metabolic institution is testimony on the importance of metabolic tests for clinical and diagnostic applications. Dr. Wishart’s expertise and TMIC’s infrastructure offers BioMark an ideal partnership.” BioMark acknowledges and is thankful for the continued support and commitment from Natural Sciences and Engineering Research Council of Canada.

 

BIOMARK ANNOUNCES GRANT FUNDED PARTNERSHIP WITH TMIC (PDF)

 

———————————————

Biomark Announces A Final Closing Private Placement

FEBRUARY 18, 2015

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia – (February 18, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF) announces that further to its press release of December 9, 2014, it has closed the final tranche of a non-brokered private placement for gross proceeds of $599,000 wherein BioMark issued 1,198,000 units at a price of $0.50 per unit. Together with the first tranche (see news release January 2, 2015), the Company has raised $750,000 of the previously announced $750,000.

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.80 per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finder’s fees are payable on the private placement.

The proceeds of the private placement will be used for the continuation of the company’s phase 3 clinical trials and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.

 

Press Release – Closing_Private Placement_release_-_February 2015 (PDF)

 

———————————————

BioMark Announces OTCQB Listing

FEBRUARY 17, 2015

Vancouver, British Columbia – (February 17, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF)commenced trading on OTCQB®, the venture market for entrepreneurial and development stage companies. OTC Markets Group announced today that BioMark Diagnostic has been verified for trading on OTCQB, effective February 17, 2015.

“We are very pleased to add BioMark to our expanding universe of OTCQB companies,” commented Douglas Rogers, Managing Director of Merriman’s Capital Markets Advisory Group. “Advising our clients on best practices regarding their material information and financial reporting requirements is a key component of our advisory platform at Merriman. We look forward to supporting the BioMark management team on the OTCQB market.”

 

Press release – BIOMARK ANNOUNCES OTCQB LISTING- February 17th (PDF)

 

———————————————

BioMark Receives US Trading Symbol BMKDF from FINRA and Commences Trading in the USA

JANUARY 14, 2015

Vancouver, British Columbia – (January 14, 2014) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE: 20B) is pleased to announce that shares of the Company have commenced trading on the OTC Pink Sheets under the symbol BMKDF.

Rashid Ahmed, President and CEO states: “This is the just the first step towards developing a shareholder base in the United States. The Company is fully reporting in Canada and is listed on the Canadian Securities Exchange as well as on the Frankfurt Stock Exchange. These multiple listings & quotation platforms will allow us to access a significantly larger base of interested American biopharma investors, providing enhanced liquidity and better valuation. We are delighted to work with Merriman Capital Inc., whose hard work and effort has allowed us to obtain our US trading symbol. The Company’s capital markets team will work to ensure that the Company meets additional requirements and take BioMark to the next level.”

 

Press Release – BioMark Receives US Trading Symbol BMKDF (PDF)

 

———————————————

BioMark To Be On CBC Early Edition

JANUARY 14, 2015

Vancouver, British Columbia – (January 14, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) will be speaking about the company’s low cost, non invasive cancer diagnostics kit on the CBC’s Early Edition with Rick Cluff today, January 14th, 2015 at 6:40 AM PST (Pacific Standard Time).

The company would like to invite our shareholders, partners and all interested parties to tune in to channel 690 on your AM dial, 88.1 FM or stream live at http://www.cbc.ca/earlyedition.

 

Press Release – BIOMARK TO BE ON CBC EARLY EDITION (PDF)

 

———————————————

BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program

NOVEMBER 25, 2014

Vancouver, British Columbia – (November 25, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has received from the Manitoba’s Ministry of Jobs and Economy a funding grant of $50,000 under Commercialization Support for Business (CSB) program which is designed for small and medium-sized businesses.
The CBS program helps Manitoba continue to move forward by supporting product and process commercialization and business development in all sectors and all regions of the province. Specifically, this funding proceeds will be focused on expanding freedom to operate opinions, product packaging and sample runs, cross-validation with third parties and market validation studies.
President and CEO Rashid Ahmed says, “We are very pleased and grateful to the government of Manitoba for this financial support as we realize technology commercialization. BioMark licensed the technology invented by Dr. Daniel Sitar at the University of Manitoba in 2006. The University has an equity stake in BioMark. BioMark is committed to delivering on all the key milestones under the application and our goal is to continue our partnership with investments in Manitoba.”

Press Release BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program (PDF)

————————————————-

 

Dr. John Yoo Joins BioMark Advisory Team

NOVEMBER 17, 2014

Yoo April 30 2013_1Vancouver, British Columbia – (November 17th, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Dr. John Yoo to its clinical advisory team.
Dr. Yoo is the Professor and Chair, City-Wide Chief, Department of Otolaryngology-Head and Neck Surgery and Professor in the Department of Oncology at the Schulich School of Medicine & Dentistry, Western University; Director of the Head and Neck Oncology & Reconstructive Surgery Program; and the Co-Chair CancerCare Ontario Head and Neck Disease Site Group.
Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome Dr. Yoo’s stature into our company. His achievements in the oncology space will be a major asset to BioMark’s group. Dr. Yoo’s clinical expertise and research experience brings depth and practicality as we position our technology for the patient care setting.”
“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment of lung tumours. BioMark’s technology could be a critically important tool for clinicians” says Dr. Yoo.

Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM – November 17, 2014 (PDF)

————————————————-

 

BioMark Announces Appointment of Bill Good

November 12, 2014

Bill_Good_2Vancouver, British Columbia – (November 12th, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Mr. Bill Good to its Advisory Board.
Veteran broadcaster Bill Good has done it all when it comes to media in Canada. Mr. Good spent fifty years on television and radio. For ten years, Mr. Good covered sports with CBC including Olympic and Commonwealth Games as well as Hockey night in Canada and co-hosted the famous Canada-Soviet hockey summit in 1972. Mr. Good left sports broadcasting in the late seventies and spent thirty years anchoring flagship early evening news at CBC, BCTV, and CTV all the while hosting the top rated Bill Good Show on CKNW.

BIOMARK_ANNOUNCES_APPOINTMENT_OF_BILL_GOOD (PDF)

————————————————-

 

BioMark Expands Phase 3 Clinical Trials

NOVEMBER 5, 2014

Vancouver, British Columbia – (November 5, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that BioMark has expanded its Phase 3 cancer screening clinical trials to include The National Institute of Cancer Research and Hospital in Bangladesh. The clinical trials are in the process of being registered with both clinicaltrials.gov and the World Health Organization (WHO).
BioMark anticipates completing 50% of the 340 patient Phase 3 clinical trial by the first quarter of 2015. Following a successful completion of the clinical trial and regulatory health approval, BioMark will commence marketing its proprietary technologies in key global markets.
Rashid Ahmed , President & CEO, states: “This is a significant achievement for BioMark. Strong research collaborators such as The National Institute of Cancer Research and Hospital in Bangladesh, in addition to long-term partners such as St-Boniface Hospital Research, CancerCare Manitoba, Surrey Memorial Hospital, have been instrumental in moving our cancer diagnostic technology forward. We look forward to completing our trials in 2015 and to offer diagnostic options that can be used solo or to complement existing cancer detection and treatment technologies.”

BIOMARK_DIAGNOSTICS_INC_EXPANDS_PHASE_3_CLINICAL_TRIALS (PDF)

————————————————-

 

BioMark Approved Listing and Commences Trading on the CSE

NOVEMBER 3, 2014

Vancouver, B.C. – (November 3, 2014) BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) is pleased to announce that it has received approval to list its Common Shares for trading on the Canadian Securities Exchange (“CSE”), and that its Common Shares have commenced trading as of the opening of market, today, November 3, 2014, under the trading symbol “BUX”.

Follow this link to the CSE: <a href=”http://www.thecse.com/CNSX/Securities/Life-Sciences/BioMark-Diagnostics-Inc.aspx” target=”_blank”>http://www.thecse.com/CNSX/Securities/Life-Sciences/BioMark-Diagnostics-Inc.aspx</a>

Biomark_Approved_for_Listing_and_Commences_Trading_on_the_CSE (PDF)

————————————————-

 

BioMark Raman SenSers Product Launch at Strategies on Biophotonics Boston September 9-11 2014

http://pubs.rsc.org/en/Content/ArticleLanding/2014/AN/c4an01309c#!divAbstract

BioMark is proud to announce the launch of its first generation Raman SERS at the first Strategies in Biophotonics conference held in Boston. The technology platform was developed by Dr. Reuven and Dr. Hof from the University of Victoria, BioMark and Innovative Photonics Solutions.

Jim Elliott, the Principal Engineer is shown below at the show along with the team from Innovative Photonics Solutions. The trio of experts are working on new developments for BioMark’s next generation of Raman analytical systems. BioMark is in negotiations with multiple partners both locally and internationally for product sales and placement later in 2014 or early 2015.

IPS and Jim_sm

Biomark Announces A Partial Closing Private Placement

JANUARY 2nd, 2015

Vancouver, British Columbia – (January 2, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) announces that further to its press release of December 9, 2014, it has closed the first tranche of a non-brokered private placement for gross proceeds of $151,000 wherein BioMark issued 302,000 units at a price of $0.50 per unit.

 

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.80 per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finder’s fees are payable on the private placement.

 

The proceeds of the private placement will be used for the continuation of the company’s phase 3 clinical trials and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.

 

Press Release-BIOMARK ANNOUNCES A PARTIAL CLOSING PRIVATE PLACEMENT-January 2, 2015 (PDF)

 

———————————————

BioMark Diagnostics, Inc. to present at the inaugural equities.com Small-Cap Stars Conference at the NASDAQ MarketSite on December 18, 2014

DECEMBER 16th, 2014

Vancouver, British Columbia – (December 16, 2014)–BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE:20B) is excited to announce that it will be presenting at the inaugural equities.com Small-Cap Stars Conference at the world-famous NASDAQ MarketSite on December 18, 2014.

The event is a gathering of the brightest emerging growth NASDAQ-listed small-cap companies to present and network with an exclusive group of top-level institutional investors. The equities.com Small-Cap Stars Conference is highlighted with a keynote presentation by legendary money manager and small-cap pioneer Ken Fisher, CEO of Fisher Investments. There will also be a special guest presentation by Rock & Roll Hall of Famer Gene Simmons, a New York Times best-selling author and Master of Brand Identity.

President and CEO of BioMark, Rashid Ahmed comments: “The equities conference provides us with an outstanding venue to update our investors and provides us with unparalleled access to major US institutions that understand the potential in the biopharma sector for Companies with advanced diagnostics solutions.”

To learn more about BioMark Diagnostics, Inc. we encourage you to visit our website at www.biomarkdiagnostics.com .

The event is for an institutional audience only. Attendees will include: Hedge Funds, Family Offices, Portfolio Managers, Investment Banks & Venture Capitalists interested in small-cap opportunities on the NASDAQ. One-on-One meetings are available for company management teams and qualified investors.

equities.com designed this full-day event dedicated to creating unparalleled discovery and exclusive networking sessions, including our Holiday Cocktail party to cap off the conference. For more details on the conference, please visit www.equitiesevents.com.

To learn more about equities.com or to become a member of our online financial community, please visit: http://www.equities.com/community/register

 

NASDAQ MarketSite (PDF)

 

———————————————

BioMark Receives Health Canada Protocol Approval

DECEMBER 8th, 2014

Vancouver, British Columbia – (December 8, 2014)–BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE:20B) is pleased to announce that BioMark has been granted an Investigational Testing Authorization (ITA”) by Health Canada’s Therapeutic Products Directorate (“TPD”) adopting the Company’s protocols and reference standards for reference laboratories across Canada. The authorization also will allow BioMark to sell up to one hundred and eighty (180) of these devices as part of the ITA for investigational purposes.

 

The ITA recognizes the proprietary protocol the Company has developed and internationally patented for urinary excretion of Acetylamantadine by cancer patients. This protocol involves the use of BioMark’s Acetylamantadine Assay Standard for Liquid Chromatography – tandem Mass Spectrometry (LC-MS/MS).  This assay was developed by BioMark in order to establish a clinical diagnostic reference standard as part of the protocol when evaluating urinary excretion of acetylamantadine as a predication cancer presence.

 

President and CEO of BioMark, Rashid Ahmed comments: “This is a necessary achievement for BioMark since we utilized industry gold standard using LC-MS/MS. The authorization provides BioMark the ability to conduct tests for validating the use of our internal system for labs and sets the stage for licensing later.”

 

The regulatory submission and documentation was guided by the regulatory team at St. Boniface Hospital Research Centre.

 

Press Release – BioMark Receives Health Canada Protocol Approval (PDF)

 

———————————————

BioMark Records First Revenues

DECEMBER 4th, 2014

Vancouver, British Columbia – (December 4, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) is pleased to announce that it has recorded its first revenue for its 1st generation, state-of-the-art Surface Enhance Raman Spectrometer (SERS) technology.

Raman Spectrometry, enhances with the BioMark’s patented use of amantadine for cancer diagnostics, will once successful trials are complete and approvals are granted, enable the low cost early detection of cancer.

This first sale of BioMark’s Raman technology is a validation of the direct investment that has been made in projects associated with SERS and is an acknowledgement that one of the technical platforms to be used in detecting small molecules, such as acetylated amantadine, is market ready. The SERS technology not only can be used to detect acetylated amantadine, but it can also be used in other biophotonic and metabalomic applications, which have global applications in the health and medical sectors.

President and CEO, Rashid Ahmed says, “We are very pleased and grateful for the hard work by BioMark’s own scientific and technical team along with leading academic and research institutions in Canada and US-based Innovative Photonic Solutions   We are proud that the first of its kind portable SERS was launched at the inaugural Strategies in Biophotonics conference, which was held in Boston in September 2014 and attended by leading scientists.  I look forward to further collaboration as the company moves forward in commercialization of the current generation technology and looking at future development of paper-SERS technology that will potentially have broad-based global biophotonic and metabolomics applications.”

 

Press Release BIOMARK RECORDS FIRST REVENUES – December 4 2014-F (PDF)

 

———————————————

Dr. Safieddin Safavi-Naeini Joins Biomark Scientific Advisory Team

DECEMBER 2nd, 2014

Vancouver, British Columbia – (December 2, 2014) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX / FSE: 20B) is pleased to announce that it has appointed Dr. Safieddin Safavi-Naeini to its technical and scientific advisory team.

Dr. Safieddin Safavi-Naeini, Ph.D. is Professor in the Electrical and Computer Engineering Department and holds NSERC/Blackberry Industrial Research Chair in Intelligent Integrated Radio and Photonics at the University of Waterloo. Dr. Safavi-Naeimi is a leading hardware expert.

Rashid Ahmed, President and CEO, comments: “Dr Safavi-Naeini’s contribution to BioMark’s technical and commercialization efforts would lever our technology platform to a different level. Dr. Safavi-Naeini brings world class expertise and we are honored to have him join our team”.

Dr. SAFIEDDIN SAFAVI-NAEINI JOINS BIOMARK SCIENTIFIC ADVISORY TEAM (PDF)

 

———————————————

BioMark Lists on Frankfurt Stock Exchange

NOVEMBER 26th, 2014

Vancouver, British Columbia – (November 26th, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) is pleased to announce that it has listed its common shares on the Frankfurt Stock Exchange (FSE) under the ticker symbol 20B, with an international securities identification number (ISIN) of CA09073K1084.
The Frankfurt Stock Exchange is the world’s third largest organized exchange-trading market as measured by trading volume. Only the Nasdaq and the New York Stock Exchanges are larger. BioMark’s shares continue to trade on the Canadian Securities Exchange as the primary market.
Rashid Ahmed, Chief Executive Officer, said: “This European listing will help to increase Biomark’s trading visibility and assist in facilitating investment into the company by European investors.”

Press Release BIOMARK LISTS ON FRANKFURT STOCK EXCHANGE – November 26, 2014 (PDF)

———————————————